Retifanlimab Plus Chemotherapy Significantly Extends Overall Survival in First-Line Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
Executive Highlights The POD1UM-304 phase 3 trial marks a significant milestone in the management of…
Posted inOncology Respiratory
Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy
This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.
Posted innews Oncology Respiratory
Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeutic option with manageable safety.
Posted inClinical Updates news Oncology Specialties
Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.